Andrew Scott Blank bought $360k of BCDA
director at BioCardia, Inc.. 288,000 shares at an average of $1.25, traded Sep 19, 2025, filed Sep 23, 2025.
Score components
- +15RoleDirector
- +15Trade size$360k at market
- +10Relative to holdingsHoldings up 83%
- +18Price context0% above the 52-week low; 63% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.7%, 3m -9.9%, 6m -14.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-029652, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 19, 2025 | POpen-market purchase Common Stockindirect: See Footnote | +288,000 | $1.25 | $360k | 634,023 | Sep 23, 2025 |
| Sep 19, 2025 | POpen-market purchase Warrant (right to buy)derivativeindirect: See Footnote | +288,000 | - | - | 602,522 | Sep 23, 2025 |
Related signals
Other insiders at BioCardia, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $1,030 1,000 shares | +0% | |
| 33Weak | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $1,995 1,900 shares | +0% | |
| 28Weak | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $872 800 shares | +0% | |
| 51Moderate | BioCardia, Inc. | Simon H Stertzer director | $104k 109,200 shares | +191% | |
| 41Moderate | BioCardia, Inc. | Peter Altman President and CEO | $2,043 2,300 shares | +1% | |
| 56Moderate | BioCardia, Inc. | Peter Altman President and CEO | $4,250 5,000 shares | +2% | |
| 43Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $1,570 1,700 shares | +1% | |
| 48Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $5,244 5,700 shares | +2% | |
| 48Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $5,202 5,100 shares | +2% | |
| 48Moderate | BCDAbuy BioCardia, Inc. | Peter Altman President and CEO | $5,550 5,000 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.